Company / R&D Expense
Doximity R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$93.0M
FY2024
5-year range
$62.4M / $93.0M
FY2020-FY2024
Trend
+13.5%
vs FY2023
Sector context
#59 of 105
Health Care
What the data says
At $93M, Doximity's r&d expense ranks #59 of 105 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $32M in FY2019 to $93M in FY2024.
Based on SEC 10-K filings.
$93M in FY2024 with a 5-year CAGR of +23.5%.
Improved from $80M to $93M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.3%
- 5-Year CAGR
- +23.5%
- 10-Year CAGR
- -
Sector benchmark
#59 of 105 in Health CareTop 56% of 105This company $93.0M Sector average $284.2M
▼
-67.3% below sector average
Key checks
Key Insights
- Doximity's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +23.5%, indicating consistent growth.
- In FY2024, r&d expense increased 13.5% year-over-year.
- Ranks #59 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- Strong profit margin: 39.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $93.0M | +13.5% |
| FY2023 | $82.0M | +2.2% |
| FY2022 | $80.2M | +28.6% |
| FY2021 | $62.4M | +42.1% |
| FY2020 | $43.9M | +35.3% |
| FY2019 | $32.4M | - |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026